| Description | Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers. |
| In vitro | Abeprazan hydrochloride的作用机制是可逆地结合到H+, K+-ATPase上。与PPIs不同，Abeprazan hydrochloride 不需要酸性环境来激活化合物[1]。 |
| In vivo | Abeprazan hydrochloride 以剂量依赖的方式抑制酸分泌。在应用了幽门结扎大鼠、大鼠胃腔灌流模型及Heidenhain囊狗模型的多项体内研究中，Abeprazan hydrochloride 对胃酸分泌的抑制效果等同于或优于已获批准的P-CAB化合物vonoprazan[1]。 |
| Synonyms | DWP14012 hydrochloride, Fexuprazan hydrochloride |
| molecular weight | 446.87 |
| Molecular formula | C19H18ClF3N2O3S |
| CAS | 1902954-87-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 40 mg/mL (89.51 mM), Sonication is recommended. |
| References | 1. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. |